Fundraising FoxAisling Capital — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
Earlens makes a hearing aid that vibrates the eardrum directly rather than using speakers to amplify sound, allowing amplification across a broad audible frequency range including higher frequencies for speech understanding.
HardwareHealthtechMedical DevicesMenlo Park, US
Rodney Perkins, M.D.(Director)William M. Facteau(Executive Officer, Director)Bernard Shay(Executive Officer)Phil Lyons(Executive Officer)Brent Edwards(Executive Officer)Greg Koskowich(Executive Officer)
Board seatSteven Elms· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Windham Capital PartnersLightstone VenturesMorgenthalerSightLine Partners
Roka Bioscience develops molecular testing assays and automated instrument systems for rapid pathogen detection in food manufacturing.
BiotechFoodTechHealthtechMedical DevicesWarren, US
Lars Boesgaard(Executive Officer)Paul G. Thomas(Executive Officer, Director)
BoardJim Barret, PhD(Director)Fred Cohen(Director)Jonathan Silverstein(Director)David McGirr(Director)
Menlo Park, US
Duke Rohlen(Chief Executive Officer)
BoardCamille Samuels(Director)Anthony Natale(Director)inReed Gaither(Director)Aftab Kherani(Director)Ron Kuppersmith(Director)
Co-investorsAPERTURE Venture PartnersCorrelation VenturesVenrockWestern Technology InvestmentHealthQuest Capital
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)inJohn McDonough(Chief Executive Officer)inTom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)in
Co-investorsAPERTURE Venture PartnersIn-Q-TelArcus VenturesFlagship VenturesFlybridge Capital PartnersJohnson & Johnson Innovation – JJDC+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Zavante Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.